Effects of bempedoic acid in clinical practice
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In all-comer populations with mixed statin-intolerance and varied background LLTs, LDL-C reductions with bempedoic acid ranged from 18% to 42%.
“In all-comer populations with mixed statin-intolerance and varied background LLTs, LDL-C reductions also ranged from 18% to 42% [23,26,28,30,31,33,43].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [26]
The Results in the paper’s abstract report a mean LDL-C reduction of 25% with bempedoic acid, and patients used varied concomitant lipid-lowering therapies. That mean falls within the cited 18%–42% range, but this paper does not report that range: its recorded individual reductions were 12.6%–57%. The Methods in the abstract describe a subsidy-eligible cohort with familial hypercholesterolemia or established vascular disease, not an all-comer population, and do not establish mixed statin-intolerance status. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Still being checked.
Cited by
Sorted by citations
Systematic literature review on the real-world effectiveness and safety of bempedoic acid
Cicero, A. F. G., Cannon, C. P., Gautam, R., Anwar, S., Ghatak, A., Sarnes, E., Powell, H. A., Chhabra, R., & Jawla, S. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100562 · Cited by 1 · see citing works
- Authors
- Benítez Toledo, M. J., Martín, S., Espildora, J., Coca, I., Sanchez, M. A., & Valdivielso, P.
- Affiliations
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- ORCID
- Valdivielso, Pedro
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2024-08
- Volume
- 395
- Pages
- 117922
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W4401601183
- Cited by
- 0
- References
- 0
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- dx.doi.org
- Locations
- Atherosclerosis (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- bempedoic acid, ezetimibe, heterozygous familial hypercholesterolemia, lipid-lowering therapy, statin intolerance, LDL cholesterol lowering, treatment outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
